We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Chromaffin Cell Tumors Diagnosed by Plasma Panel

By LabMedica International staff writers
Posted on 19 Nov 2018
Pheochromocytomas and paragangliomas include adrenal and extraadrenal chromaffin cell tumors as well as head and neck paragangliomas and measurements of plasma or urinary metanephrines are recommended for diagnosis of pheochromocytoma and paraganglioma (PPGL).

Current clinical practice guidelines stipulate with a high level of evidence that biochemical screening for PPGLs should include measurements of plasma free or urinary fractionated metanephrines that is normetanephrine and metanephrine, with no recommendation concerning preference of either test.

An international team of scientists led by those at Technische Universität Dresden (Dresden, Germany) screened a study population included 2,056 patients (1,011 male) with a median age of 53 years (range, 10–93 years) for PPGLs. More...
A reference population of 351 normotensive (132 male) and 239 hypertensive (129 male) volunteers with a median age of 42 years (range, 18–82 years) was also included for establishing reference intervals.

Blood samples collected into heparinized tubes were placed on ice or cool pads at 4 °C before centrifugation to separate plasma. On the final day of collection, 24-hour urine specimens were returned to study centers. Urine volumes were then determined and samples aliquoted. Measurements of plasma and urinary metanephrines (normetanephrine, metanephrine) and methoxytyramine were performed at a single laboratory using liquid chromatography tandem mass spectrometry (LC-MS/MS), with a AB Sciex QTRAP 5500 triple quadrupole mass spectrometer.

The scientists reported that measurements of plasma free metabolites offered higher diagnostic sensitivity (97.9%) than urinary free (93.4%) and deconjugated (92.9%) metabolites at identical specificities for plasma and urinary free metabolites (94.2%) but at a lower specificity for deconjugated metabolites (92.1%). The addition of methoxytyramine offered little value for urinary panels, but provided higher diagnostic performance for plasma measurements than either urinary panel according to areas under ROC curves. Diagnostic performance of urinary and plasma tests was similar for patients at low risk of disease, whereas plasma measurements were superior to both urinary panels for high-risk patients.

The authors concluded that the diagnosis of PPGLs using plasma or urinary free metabolites provides advantages of fewer false-positive results compared with commonly measured deconjugated metabolites. The plasma panel offers better diagnostic performance than either urinary panel for patients at high risk of disease and, with appropriate preanalytics, provides the test of choice. Measurements of methoxytyramine in urine show limited diagnostic utility compared with plasma. The study was published in the October 2018 issue of the journal Clinical Chemistry.

Related Links:
Technische Universität Dresden


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.